Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199
© 2023. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society..
Adhesion molecules play essential roles in the homeostatic regulation and malignant transformation of hematopoietic cells. The dysregulated expression of adhesion molecules in leukemic cells accelerates disease progression and the development of drug resistance. Thus, targeting adhesion molecules represents an attractive anti-leukemic therapeutic strategy. In this study, we investigated the prognostic role and functional significance of cytohesin-1 (CYTH1) in acute myeloid leukemia (AML). Analysis of AML patient data from the GEPIA and BloodSpot databases revealed that CYTH1 was significantly overexpressed in AML and independently correlated with prognosis. Functional assays using AML cell lines and an AML xenograft mouse model confirmed that CYTH1 depletion significantly inhibited the adhesion, migration, homing, and engraftment of leukemic cells, delaying disease progression and prolonging animal survival. The CYTH1 inhibitor SecinH3 exerted in vitro and in vivo anti-leukemic effects by disrupting leukemic adhesion and survival programs. In line with the CYTH1 knockdown results, targeting CYTH1 by SecinH3 suppressed integrin-associated adhesion signaling by reducing ITGB2 expression. SecinH3 treatment efficiently induced the apoptosis and inhibited the growth of a panel of AML cell lines (MOLM-13, MV4-11 and THP-1) with mixed-lineage leukemia gene rearrangement, partly by reducing the expression of the anti-apoptotic protein MCL1. Moreover, we showed that SecinH3 synergized with the BCL2-selective inhibitor ABT-199 (venetoclax) to inhibit the proliferation and promote the apoptosis of ABT-199-resistant leukemic cells. Taken together, our results not only shed light on the role of CYTH1 in cell-adhesion-mediated leukemogenesis but also propose a novel combination treatment strategy for AML.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Acta pharmacologica Sinica - 45(2024), 1 vom: 29. Jan., Seite 180-192 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ren, Wen-Xiang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ABT-199 |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 08.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41401-023-01142-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361420382 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361420382 | ||
| 003 | DE-627 | ||
| 005 | 20240114231931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41401-023-01142-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1252.xml |
| 035 | |a (DE-627)NLM361420382 | ||
| 035 | |a (NLM)37644132 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ren, Wen-Xiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society. | ||
| 520 | |a Adhesion molecules play essential roles in the homeostatic regulation and malignant transformation of hematopoietic cells. The dysregulated expression of adhesion molecules in leukemic cells accelerates disease progression and the development of drug resistance. Thus, targeting adhesion molecules represents an attractive anti-leukemic therapeutic strategy. In this study, we investigated the prognostic role and functional significance of cytohesin-1 (CYTH1) in acute myeloid leukemia (AML). Analysis of AML patient data from the GEPIA and BloodSpot databases revealed that CYTH1 was significantly overexpressed in AML and independently correlated with prognosis. Functional assays using AML cell lines and an AML xenograft mouse model confirmed that CYTH1 depletion significantly inhibited the adhesion, migration, homing, and engraftment of leukemic cells, delaying disease progression and prolonging animal survival. The CYTH1 inhibitor SecinH3 exerted in vitro and in vivo anti-leukemic effects by disrupting leukemic adhesion and survival programs. In line with the CYTH1 knockdown results, targeting CYTH1 by SecinH3 suppressed integrin-associated adhesion signaling by reducing ITGB2 expression. SecinH3 treatment efficiently induced the apoptosis and inhibited the growth of a panel of AML cell lines (MOLM-13, MV4-11 and THP-1) with mixed-lineage leukemia gene rearrangement, partly by reducing the expression of the anti-apoptotic protein MCL1. Moreover, we showed that SecinH3 synergized with the BCL2-selective inhibitor ABT-199 (venetoclax) to inhibit the proliferation and promote the apoptosis of ABT-199-resistant leukemic cells. Taken together, our results not only shed light on the role of CYTH1 in cell-adhesion-mediated leukemogenesis but also propose a novel combination treatment strategy for AML | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ABT-199 | |
| 650 | 4 | |a CYTH1 | |
| 650 | 4 | |a MCL1 | |
| 650 | 4 | |a SecinH3 | |
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a cell adhesion | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 650 | 7 | |a cytohesin-1 |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Cell Adhesion Molecules |2 NLM | |
| 700 | 1 | |a Guo, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Sheng-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Si-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Yao-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Liu-Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Yu-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Jiao |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Bian-Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Hong-Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, He |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ya-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, An-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yi-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Ke-Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhi-Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qiu-Bai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmacologica Sinica |d 2000 |g 45(2024), 1 vom: 29. Jan., Seite 180-192 |w (DE-627)NLM111735181 |x 1745-7254 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:1 |g day:29 |g month:01 |g pages:180-192 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41401-023-01142-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 1 |b 29 |c 01 |h 180-192 | ||